NASDAQ:ALLK
Allakos Inc. Stock News
$1.44
-0.0100 (-0.690%)
At Close: May 17, 2024
Allakos: Potential For Comeback With Lirentelimab With 2 Indications
03:22am, Tuesday, 18'th Oct 2022
Results from the phase 2b study, using lirentelimab for the treatment of patients with chronic spontaneous urticaria, are expected in the 2nd half of 2023. Xolair naive CSU cohort of 13 patients start
Alkermes, Allakos See Activist Action
06:35pm, Friday, 14'th Oct 2022
These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities.
3 Healthcare Stocks to Sell Before They Die
11:48am, Friday, 30'th Sep 2022
The Fed's key interest rate target now stands at 3%-3.25%, way up from 0%-0.25% at the beginning of the year. That means, for all companies, borrowing money is becoming much more expensive.
Why Is Allakos (ALLK) Stock Soaring 25% Today?
12:56pm, Monday, 19'th Sep 2022
On Monday, biotechnology firm Allakos (NASDAQ: ALLK ) announced a public offering that raised gross proceeds of approximately $150 million, sending ALLK stock soaring 25% in the morning session before
Why Allakos Stock Is on Fire Today
02:10pm, Wednesday, 31'st Aug 2022
Investors appear to be getting into position ahead of a major upcoming catalyst.
A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street
10:38am, Monday, 09'th May 2022 Benzinga
Pre-open movers
U.S. stock futures traded lower in early pre-market trade after the Dow Jones dropped around 100 points in the previous session. Investors are awaiting earnings results from Exelon Co
5 Stocks To Watch For May 9, 2022
09:07am, Monday, 09'th May 2022 Benzinga
Some of the stocks that may grab investor focus today are:
Wall Street expects Exelon Corporation (NASDAQ: EXC) to report quarterly earnings at $0.66 per share on revenue of $4.62 billion before the
Allakos Provides Business Update and Reports First Quarter 2022 Financial Results
08:05pm, Friday, 06'th May 2022 GlobeNewswire Inc.
REDWOOD CITY, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergi
Allakos Inc. (ALLK) Stock Sinks As Market Gains: What You Should Know
10:00pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Allakos Inc. (ALLK) closed at $3.86 in the latest trading session, marking a -1.03% move from the prior day.
Allakos Inc. (ALLK) Stock Moves -1.6%: What You Should Know
10:00pm, Friday, 22'nd Apr 2022 Zacks Investment Research
Allakos Inc. (ALLK) closed the most recent trading day at $4.31, moving -1.6% from the previous trading session.
Allakos Inc. (ALLK) Stock Sinks As Market Gains: What You Should Know
10:15pm, Tuesday, 19'th Apr 2022 Zacks Investment Research
In the latest trading session, Allakos Inc. (ALLK) closed at $4.80, marking a -1.64% move from the previous day.
Allakos Inc. (ALLK) Gains As Market Dips: What You Should Know
10:15pm, Tuesday, 12'th Apr 2022 Zacks Investment Research
In the latest trading session, Allakos Inc. (ALLK) closed at $5.46, marking a +0.18% move from the previous day.
Allakos Inc. (ALLK) Stock Sinks As Market Gains: What You Should Know
10:15pm, Monday, 28'th Mar 2022 Zacks Investment Research
Allakos Inc. (ALLK) closed the most recent trading day at $5.69, moving -0.52% from the previous trading session.
Allakos Inc. (ALLK) Outpaces Stock Market Gains: What You Should Know
10:15pm, Tuesday, 22'nd Mar 2022 Zacks Investment Research
Allakos Inc. (ALLK) closed at $5.97 in the latest trading session, marking a +1.7% move from the prior day.
Allakos Inc. (ALLK) Stock Sinks As Market Gains: What You Should Know
10:00pm, Tuesday, 15'th Mar 2022 Zacks Investment Research
Allakos Inc. (ALLK) closed at $5.08 in the latest trading session, marking a -0.39% move from the prior day.
